AI-generated summary
This narrative review describes recent advances in dry eye disease management across pharmacologic agents, device-based treatments, patient stratification, and long-term care models. The authors report that newer therapies include anti-inflammatory drugs, a nasal spray, and devices such as thermal pulsation and intense pulsed light, and they emphasize phenotype-driven, personalized care. As a narrative review, the paper does not report pooled study results or a quantitative comparison of treatment effects.
- Who or what was studied
- Patients with dry eye disease
- Limits stated in the abstract
- As a narrative review, the abstract reports no systematic search, pooled data, or quantified treatment effects.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Dry eye, Inflammation, Heterogeneity. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.